Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a strong sell rating to a hold rating in a report published on Monday,Zacks.com reports.

Several other equities research analysts also recently issued reports on MIST. Wells Fargo & Company decreased their price objective on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a research note on Thursday, May 14th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Finally, Raymond James Financial started coverage on shares of Milestone Pharmaceuticals in a report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.25.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $1.30 on Monday. The stock’s 50-day moving average is $1.40 and its 200-day moving average is $1.66. The company has a market cap of $161.85 million, a price-to-earnings ratio of -1.91 and a beta of 0.97. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.18 and a quick ratio of 9.09. Milestone Pharmaceuticals has a 12 month low of $1.00 and a 12 month high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its earnings results on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.26). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $30.11 million. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.97 earnings per share for the current year.

Insider Transactions at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 36,500 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares in the company, valued at $1,008,511.44. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.03% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Strategic Family Wealth Counselors L.L.C. acquired a new stake in Milestone Pharmaceuticals during the 4th quarter valued at $25,000. Eaton Financial Holdings Company LLC acquired a new position in Milestone Pharmaceuticals in the 4th quarter worth $26,000. Welch & Forbes LLC acquired a new position in Milestone Pharmaceuticals in the 1st quarter worth $30,000. Bank of America Corp DE lifted its holdings in Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after buying an additional 16,044 shares in the last quarter. Finally, Cetera Investment Advisers purchased a new position in Milestone Pharmaceuticals in the 4th quarter valued at about $42,000. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.